Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
Clinical Infectious Diseases2022Vol. 76(3), pp. e1177–e1185
Citations Over TimeTop 1% of 2022 papers
Ahmed Musa, Jane Mbui, Rezika Mohammed, Joseph Olobo, Koert Ritmeijer, Gabriel Alcoba, Gina Muthoni Ouattara, Thaddaeus Egondi, P Nakanwagi, Truphosa Omollo, Monique Wasunna, Luka Verrest, Thomas P. C. Dorlo, Brima M. Younis, A. R. O. Abdel Nour, Elmukashfi Taha Ahmed Elmukashfi, Ahmed Ismail Omer Haroun, Eltahir Awad Gasim Khalil, Simon Njenga, Helina Fikre, Tigist Mekonnen, Dagnew Mersha, Kasaye Sisay, Patrick Sagaki, Jorge Alvar, Alexandra Solomos, Fabiana Alves
Abstract
NCT03129646.
Related Papers
- → Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?(2007)209 cited
- Visceral leishmaniasis (kala-azar): challenges ahead.(2006)
- → An update on small molecule strategies targeting leishmaniasis(2018)67 cited
- → Oral miltefosine treatment in children with visceral leishmaniasis: a brief review(2008)25 cited
- → A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy(2011)15 cited